Prognostic relevance of myelodysplasia in de novo and secondary AML.

被引：0
|
作者：
Schaekel, U [1 ]
Brocard, B [1 ]
Kroschinsky, F [1 ]
Schaich, M [1 ]
Soucek, S [1 ]
Neubauer, A [1 ]
Ehninger, G [1 ]
机构：
[1] Tech Univ Dresden, Univ Klinikum CG Carus, Med Klin & Poliklin 1, Study Ctr AML96,Study Grp, D-8027 Dresden, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
453
引用
收藏
页码：106A / 106A
页数：1
相关论文
共 50 条
  • [31] Telomere length is an independent prognostic marker in MDS but not in de novo AML
    Williams, Jenna
    Heppel, Nicole H.
    Britt-Compton, Bethan
    Grimstead, Julia W.
    Jones, Rhiannon E.
    Tauro, Sudhir
    Bowen, David T.
    Knapper, Steven
    Groves, Michael
    Hills, Robert K.
    Pepper, Chris
    Baird, Duncan M.
    Fegan, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (02) : 240 - 249
  • [32] Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML.
    Karp, J. E.
    Rizzieri, D.
    Vey, N.
    Mufti, G.
    Geller, R.
    O'Brien, S.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 340S - 340S
  • [33] MORPHOLOGICAL COMPARISON OF DYSPLASTIC CHANGES BETWEEN DE-NOVO ACUTE MYELOID-LEUKEMIA (AML) WITH TRILINEAGE MYELODYSPLASIA AND AML DEVELOPED FROM DE-NOVO MYELODYSPLASTIC SYNDROMES
    KURIYAMA, K
    MIYAZAKI, Y
    ARIMURA, K
    NAGAI, K
    NAKAMURA, H
    MATSUO, T
    TOMONAGA, M
    LEUKEMIA RESEARCH, 1995, 19 (02) : 121 - 125
  • [34] Evaluation of prognostic factors after induction therapy in AML.
    Devoe, Craig E.
    Bao, Delong
    Trotta, Christina
    Lee, Chung-Shien
    Fishbein, Joanna Stein
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
    Baron, Frederic
    Nagler, Arnon
    Galimard, Jacques-Emmanuel
    Sanz, Jaime
    Broers, A. E. C.
    Forcade, Edouard
    Chevalier, Patrice
    Sirvent, Anne
    Nicholson, Emma
    Kuball, Jurgen
    Furst, Sabine
    Rambaldi, Alessandro
    Sierra, Jorge
    Borne, Peter A. Von dem
    Hernanz, Maria Pilar Gallego
    Cluzeau, Thomas
    Robinson, Stephen
    Raiola, Anna Maria
    Labussiere-Wallet, Helene
    Byrne, Jenny L.
    Malfuson, Jean-Valere
    Ruggeri, Annalisa
    Mohty, Mohamad
    Ciceri, Fabio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 153 - 154
  • [36] Assessment of Myeloid And Monocytic Dysplasia by Flow Cytometry in De Novo AML Helps Define an AML with Myelodysplasia-Related Changes Category
    Weinberg, Olga K.
    Hasserjian, Robert P.
    Li, Betty
    Pozdnyakova, Olga
    LABORATORY INVESTIGATION, 2016, 96 : 383A - 383A
  • [37] Influence of age on prognosis varies between distinct cytogenetic subgroups: A study on 1225 patients with de novo AML.
    Schoch, C
    Kern, W
    Schnittger, S
    Hiddemann, W
    Haferlach, T
    BLOOD, 2003, 102 (11) : 601A - 601A
  • [38] Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category
    Weinberg, Olga K.
    Hasserjian, Robert P.
    Li, Betty
    Pozdnyakova, Olga
    JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (02) : 109 - 115
  • [39] Detection of minimal residual disease with double flow cytometry - Atypical antigen combinations in patients with de novo AML.
    Plata, E
    ChoremiPapadopoulou, H
    Viglis, V
    Viniou, N
    Konstantopoulos, K
    Meletis, J
    Loukopoulos, D
    Yataganas, X
    BLOOD, 1996, 88 (10) : 2235 - 2235
  • [40] Assessment of Myeloid And Monocytic Dysplasia by Flow Cytometry in De Novo AML Helps Define an AML with Myelodysplasia-Related Changes Category
    Weinberg, Olga K.
    Hassedian, Robert P.
    Li, Betty
    Pozdnyakova, Olga
    MODERN PATHOLOGY, 2016, 29 : 383A - 383A
12345